Department of Health and Social Care written question – answered at on 11 December 2023.
Karl McCartney
Conservative, Lincoln
To ask the Secretary of State for Health and Social Care, with reference to the policy paper entitled 2024 voluntary scheme for branded medicines pricing, access and growth: summary of the heads of agreement, published on 20 November 2023, what assessment her Department has made of the potential impact of these policies on life science SMEs.
Andrew Stephenson
Assistant Whip, Minister of State (Department of Health and Social Care)
The Government’s Life Sciences Vision sets out our ambition to develop a globally competitive life sciences investment ecosystem in the United Kingdom. While no assessment has been made, the 2024 voluntary scheme for branded medicines pricing, access and growth includes several policies that will benefit innovative companies and drive innovation into the United Kingdom. This includes an exemption from payment for small companies with under £6m of sales to the National Health Service and a taper for medium sized companies with between £6 million and £30 million of sales.
Yes2 people think so
No2 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.
Secretary of State was originally the title given to the two officials who conducted the Royal Correspondence under Elizabeth I. Now it is the title held by some of the more important Government Ministers, for example the Secretary of State for Foreign Affairs.
